LOGIN
Oral alendronate cannot yet be recommended for children with OI
July 2014
Oral alendronate cannot yet be recommended for children with OI
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study
J Clin Endocrinol Metab. 2011 Feb;96(2):355-64Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
139 children and adolescents with moderate to severe osteogenesis imperfecta (OI) were randomized to evaluate the safety and efficacy of oral alendronate (ALN). The trial primarily focused on the assessment of lumbar spine bone mineral density (LS BMD) alongside several secondary critera/data: clinical, radiological, biochemical, and multiple bone-related measurements and fracture details. Results...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.